Zacks: Brokerages Anticipate Kamada Ltd. (NASDAQ:KMDA) to Post $0.04 Earnings Per Share

Equities analysts predict that Kamada Ltd. (NASDAQ:KMDA) will post earnings per share of $0.04 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Kamada’s earnings, with the highest EPS estimate coming in at $0.06 and the lowest estimate coming in at $0.01. Kamada reported earnings of $0.09 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 55.6%. The firm is scheduled to issue its next earnings results on Wednesday, August 11th.

On average, analysts expect that Kamada will report full year earnings of $0.14 per share for the current financial year, with EPS estimates ranging from $0.07 to $0.23. For the next fiscal year, analysts forecast that the company will post earnings of $0.11 per share, with EPS estimates ranging from ($0.11) to $0.32. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Kamada.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Wednesday, May 12th. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Kamada had a net margin of 15.60% and a return on equity of 12.89%.

Shares of NASDAQ:KMDA traded down $0.19 during trading on Thursday, reaching $5.67. The stock had a trading volume of 133,617 shares, compared to its average volume of 173,151. Kamada has a one year low of $5.55 and a one year high of $13.33. The company has a market capitalization of $252.43 million, a P/E ratio of 11.81 and a beta of 1.10. The firm’s 50-day simple moving average is $6.10 and its 200 day simple moving average is $6.56.

Several large investors have recently added to or reduced their stakes in KMDA. Marshall Wace LLP bought a new stake in shares of Kamada in the 1st quarter valued at about $276,000. Morgan Stanley boosted its stake in Kamada by 14.5% in the 3rd quarter. Morgan Stanley now owns 382,590 shares of the biotechnology company’s stock worth $3,199,000 after purchasing an additional 48,398 shares in the last quarter. BlackRock Inc. boosted its stake in Kamada by 5,859.2% in the 4th quarter. BlackRock Inc. now owns 397,297 shares of the biotechnology company’s stock worth $2,575,000 after purchasing an additional 390,630 shares in the last quarter. Seizert Capital Partners LLC boosted its stake in Kamada by 118.3% in the 4th quarter. Seizert Capital Partners LLC now owns 46,012 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 24,934 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Kamada by 143,613.3% in the 4th quarter. Wells Fargo & Company MN now owns 140,839 shares of the biotechnology company’s stock worth $913,000 after purchasing an additional 140,741 shares in the last quarter. Institutional investors and hedge funds own 14.25% of the company’s stock.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

See Also: Can individual investors take part in an IPO?

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.